Employees: 3,114
Size Cisen Pharmaceutical (603367.SS) is a China Health Care company (Medical Specialties) with a market value of $843M, the 2489th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.65 on 18 Nov 2026.
Performance Over six months the shares fell 14.6%, against -14.0% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue fell 6.4% over the last twelve months (peer median +10.4%); the operating margin is 8.2% (peer median 10.0%).
Valuation It trades at 7.9× forward earnings against a peer median of 26.0× (cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.9 points above its cost of capital (6.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.34B | CN¥3.42B | CN¥3.95B | CN¥4.42B | CN¥4.03B |
| Revenue growth | — | -14% | -11% | +10% | — |
| Gross profit | CN¥1.83B | CN¥1.66B | CN¥2.09B | CN¥2.46B | CN¥2.14B |
| EBITDA | n/a | CN¥458M | CN¥639M | CN¥749M | CN¥522M |
| Net income | CN¥387M | CN¥421M | CN¥509M | CN¥521M | CN¥350M |
| Free cash flow | CN¥578M | CN¥555M | CN¥533M | CN¥480M | CN¥259M |
| Capital expenditure | CN¥8.59M | CN¥64.8M | CN¥102M | CN¥17.7M | CN¥35.2M |
| Total debt | CN¥252M | CN¥399M | CN¥576M | CN¥529M | CN¥478M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603367.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.9% | -6.4% | 8th lowest of 21 |
| 6-month return | -14.6% | -14.0% | 11th highest of 21 |
| Distance from 52-week high | -42.5% | -41.1% | 10th lowest of 21 |
| Revenue growth (TTM) | -6.4% | +10.4% | 2nd lowest of 21 |
| Operating margin | 8.2% | 10.0% | 9th lowest of 21 |
| Forward P/E | 7.9× | 26.0× | cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -14.6% | 9.3% | least demanding of 13 |
| Growth delivered (Del g) | -1.3% | +12.2% | 2nd lowest of 13 |
| Hurdle (Req g minus delivered) | -13.3 pp | -2.7 pp | 3rd least demanding of 13 |
| ROIC minus cost of capital | +3.9 pp | +1.5 pp | 7th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cisen Pharmaceutical 603367.SS | China | $843M | -15% | -6% | 8% | 7.9× | -14.6% | -1.3% |
| Modern Dental 3600.HK | Hong Kong | $844M | +24% | +12% | 22% | 8.5× | -7.1% | +11.3% |
| Cofoe Medical Technology 1187.HK | Hong Kong | $836M | -11% | +40% | 10% | 13.1× | -6.4% | +6.6% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $858M | -25% | +4% | 30% | n/a | 11.1% | +4.6% |
| HOB Biotech 688656.SS | China | $858M | -33% | +6% | 7% | 166.9× | 37.6% | +12.4% |
| OrthoPediatrics KIDS | United States | $826M | +71% | +16% | -8% | n/a | n/a | n/a |
| Beijing SDL Technology 002658.SZ | China | $864M | -34% | -13% | 9% | 22.4× | 16.8% | +2.9% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $818M | -36% | +36% | 16% | n/a | 35.6% | +17.1% |
| Tinavi Medical Technologies 688277.SS | China | $872M | -36% | -2% | -59% | n/a | n/a | n/a |
| Beijing Hotgen Biotech 688068.SS | China | $815M | -37% | +8% | -94% | n/a | n/a | n/a |
| MedCap MCAP.ST | Sweden | $811M | -4% | +17% | 15% | 25.8× | 2.7% | +20.9% |
| Advanced Medical Solutions AMS.L | United Kingdom | $811M | +27% | +6% | 12% | 20.7× | 20.0% | +21.4% |
| Xiangyu Medical 688626.SS | China | $877M | -38% | 0% | 4% | 56.2× | n/a | n/a |
| Hangzhou Biotest Biotech 688767.SS | China | $878M | -12% | -4% | 3% | 37.0× | n/a | n/a |
| Seegene 096530.KS | South Korea | $808M | -26% | +13% | 13% | 20.0× | -6.7% | -15.9% |
| Shenzhen YHLO Biotech 688575.SS | China | $882M | -16% | +3% | 12% | 30.7× | 2.0% | +12.7% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $888M | -12% | +17% | 18% | 26.2× | 19.3% | +23.3% |
| Bioventus BVS | United States | $895M | -3% | +4% | 10% | 13.0× | 7.5% | +12.1% |
| Artivion AORT | United States | $905M | -18% | +14% | 5% | 383.6× | n/a | n/a |
| Kuros Biosciences KURN.SW | Switzerland | $907M | -12% | +41% | 6% | 70.5× | n/a | n/a |
| Standard Engineering Technology SETL.NS | India | $783M | +168% | +45% | 14% | n/a | n/a | n/a |